



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kimberly A. Gillis, Ph.D., et al.  
Application No. : Not Yet Assigned  
Filed : November 28, 2001  
Entitled : EXPRESSION ANALYSIS OF  
INHIBITOR OF DIFFERENTIATION  
NUCLEIC ACIDS AND  
POLYPEPTIDES USEFUL IN THE  
DIAGNOSIS AND TREATMENT OF  
PROSTATE CANCER  
Docket No. : 102729-14

Group Art Unit:

Examiner: Not Yet Assigned

Certificate of Mailing (37 C.F.R. 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service Post Office as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

February 27, 2002	By:
Date of Signature and Mail Deposit	Jasbir Sagoo Reg. No: P-51177

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:


Applicant hereby cites for the record in this application the enclosed documents listed on the attached copy of PTO Form 1449. The enclosed Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. Accordingly, Applicant believes that no fee or certification is required.

The Assistant Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 141449.

Respectfully submitted,


NUTTER, MCCLENNEN & FISH, LLP

Date: February 27, 2002

  
\_\_\_\_\_  
Jasbir Sagoo  
Reg. No. P-51177  
Agent for Applicants

One International Place  
Boston, MA 02110-2699  
Tel: (617)439-2994  
Fax: (617)310-9994

1081954.1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Patent Mark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	November 28, 2001
				First Named Inventor	Kimberly A. Gillis, Ph.D., et al.
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	102729-14

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	5,030,559	07-09-1991	Nicolson et al.	
	AB	5,118,611	06-02-1992	Smith et al.	
	AC	5,629,007	05-13-1997	Audia et al.	
	AD	5,635,197	06-03-1997	Audia et al.	
	AE	5,674,682	10-07-1997	Croce et al.	
	AF	5,688,658	11-18-1997	Diamandis	
	AG	5,723,302	03-03-1998	Diamandis	
	AH	5,763,202	06-09-1998	Horoszewicz	
	AI	5,843,994	12-01-1998	Samid	
	AJ	5,854,206	12-29-1998	Twardzik et al.	
	AK	5,856,112	01-05-1999	Marley et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 97/08318	03-06-1997	Corixa Corporation		
	BB	WO 97/33909	09-18-1997	Corixa Corporation		
	BC	WO 98/37093	08-27-1998	Corixa Corporation		
	BD	WO 98/37418	08-27-1998	Corixa Corporation		
	BE	WO 99/18210	04-15-1999	Corixa Corporation		
	BF	WO 99/37811	07-29-1999	UROCOR, Inc.		
	BG	WO 00/04149	01-27-2000	Corixa Corporation		
	BH	WO 00/14234	03-16-2000	UROCOR, Inc.		
	BI	WO 00/18961	04-06-2000	Millennium Pharmaceuticals, Inc.		
	BJ	WO 01/66784 A1	09-13-2001	Sloan-Kettering Institute For Cancer Research		
	BK	EP 0 648 126 B1	02-02-2000	Procyon Biopharma, Inc.		
	BL	EP 0 698 215 B1	07-15-1998	Nordion International, Inc.		
	BM	EP 0 974 652 A1	01-26-2000	Banyu Pharmaceutical Co., Ltd.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Asp et al., "The Helix-Loop-Helix Transcription Factors Id1 and Id3 Have a Functional Role in Control of Cell Division in Human Normal and Neoplastic Chondrocytes," <i>FEBS Letters</i> , Vol. 438, 1998, pp. 85-90	
	CB	Barone et al., "Id Proteins Control Growth Induction in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, May 1994, pp 4985-4988	



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031


U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete If Known</b>		
			Application Number	Not Yet Assigned	
			Filing Date	November 28, 2001	
			First Named Inventor	Kimberly A. Gillis, Ph.D., et al.	
			Group Art Unit		
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	102729-14

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AL	5,861,248	01-19-1999	Russell et al.	
	AM	5,882,864	03-16-1999	An et al.	
	AN	5,939,258	08-17-1999	Croce et al.	
	AO	5,945,522	08-31-1999	Cohen et al.	
	AP	5,972,615	10-26-1999	An et al.	
	AQ	5,976,794	11-02-1999	Katz et al.	
	AR	5,976,838	11-02-1999	Jacobs et al.	
	AS	6,025,137	02-15-2000	Shyjan	
	AT	6,028,174	02-22-2000	Ullrich et al.	
	AU	6,034,218	03-07-2000	Reed et al.	
	AV	6,051,230	04-18-2000	Thorpe et al.	
	AW	6,054,265	04-25-2000	Barney et al.	
	AX	6,252,058 B1	06-26-2001	Thompson	
	AY	6,261,535 B1	07-17-2001	Thorpe et al.	
	AZ	6,261,766 B1	07-17-2001	Diamandis	
	AAA	6,319,891 B1	11-20-2001	Sontheimer et al.	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CC	Cleutjens, et al., "Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter," <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 11, March 15, 1996, pp 6379-6388	
	CD	Henttu, et al., "Androgens Up-Regulate the Human Prostate-Specific Antigen Messenger Ribonucleic Acid (mRNA), but Down-Regulate the Prostatic Acid Phosphatase mRNA in the LNCaP Cell Line," <i>Endocrinology</i> , Vol. 130, No. 2, 1992, pp 772	
	CE	Horszewicz, et al., "LNCaP Model of Human Prostatic Carcinoma <sup>1</sup> ," <i>Cancer Research</i> , Vol 43, April 1983, pp 1809-1818	
	CF	Inoue et al., "MIDA1, an Id-Associating Protein, Has Two Distinct DNA Binding Activities That Are Converted by the Association with Id1: A Novel Function of Id Protein," <i>Biochemical and Biophysical Research Communications</i> , Vol. 266, 1999, pp 147-151	
	CG	Kokontis, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation <sup>1</sup> ," <i>Cancer Research</i> , Vol. 54, March 15, 1992, pp 1566-1573	
	CH	Lassar, et al., "Regulatory Mechanisms That Coordinate Skeletal Muscle Differentiation and Cell Cycle Withdrawal," <i>Current Opinion in Cell Biology</i> , Vol. 6, 1994 pp 788-794	
	CI	Lin et al., "A Role for Id-1 in the Aggressive Phenotype and Steroid Hormone Response of Human Breast Cancer Cells," <i>Cancer Research</i> , Vol. 60, March 1, 2000, pp 1332-1340	
	CJ	Lyden et al., "Id1 and Id3 Are Required For Neurogenesis, Angiogenesis and Vascularization of Tumor Xenografts," <i>Nature</i> , Vol. 401, Oct. 14, 1999, pp. 670-677	
	CK	Murtha, et al., "Androgen Induction of a Human Prostate-Specific Kallikrein, hKLK2: Characterization of an Androgen Response Element in the 5' Promoter Region of the Gene <sup>†</sup> ," <i>Biochemistry</i> , Vol. 32, 1993, pp 6459-6464	



PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>			
		<b>Application Number</b>	Not Yet Assigned		
		<b>Filing Date</b>	November 28, 2001		
		<b>First Named Inventor</b>	Kimberly A. Gillis, Ph.D., et al.		
		<b>Group Art Unit</b>			
		<b>Examiner Name</b>	Not Yet Assigned		
<b>Sheet</b>	3	<b>of</b>	3	<b>Attorney Docket Number</b>	102729-14

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
<b>Examiner Initials</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T<sup>2</sup></b>
	CL	Norton, <i>et al.</i> , "Id Helix-Loop-Helix Proteins in Cell Growth and Differentiation," <i>Cell Biology</i> , Vol. 8, February 1998, pp 58-65	
	CM	Prabhu, <i>et al.</i> , "Regulation of the Expression of Cyclin-Dependent Kinase Inhibitor p21 By E2A and Id Proteins," <i>Mol. and Cell. Biology</i> , Vol. 17, No. 10, Oct. 1997, pp 5888-96	
	CN	Schuermans, <i>et al.</i> , "Regulation Of Growth Of LNCaP Human Prostate Tumor Cells By Growth Factors And Steroid Hormones," <i>J. Steroid Biochem. Molec. Biol.</i> , Vol. 40, No. 1-3, 1991, pp 193-197	
	CO	Swinnen, <i>et al.</i> , "Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP," <i>Molecular and Cellular Endocrinology</i> , Vol. 104, 1994, pp 153-162	
	CP	Swinnen, <i>et al.</i> , "Androgens Markedly Stimulate the Accumulation of Neutral Lipids in the Human Prostatic Adenocarcinoma Cell Line LNCaP," <i>Endocrinology</i> , Vol. 137, No. 10, 1996, pp 4468-4474	
	CQ	Sumangala <i>et al.</i> , "Regulation of the Expression of Cyclin-Dependent Kinase Inhibitor p21 by E2A and Id Proteins," <i>Molecular and Cellular Biology</i> , Vol. 17, No. 10, Oct. 1997, pp 5888-5896	
	CR	Ulrix <i>et al.</i> , "Androgens Down-Regulate the Expression of the Human Homologue of Paternally Expressed Gene-3 in the Prostatic Adenocarcinoma Cell Line LNCaP," <i>Molecular and Cellular Endocrinology</i> , Vol. 155, 1999, pp 69-76	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.